<SEC-DOCUMENT>0001193125-23-044236.txt : 20230222
<SEC-HEADER>0001193125-23-044236.hdr.sgml : 20230222
<ACCEPTANCE-DATETIME>20230222090534
ACCESSION NUMBER:		0001193125-23-044236
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230221
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230222
DATE AS OF CHANGE:		20230222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		23650663

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8582514400

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d457589d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:hrtx="http://www.herontx.com/20230221" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2023-02-21_to_2023-02-21">HERON THERAPEUTICS, INC. /DE/</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2023-02-21_to_2023-02-21">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-02-21_to_2023-02-21">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-02-21_to_2023-02-21">0000818033</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="hrtx-20230221.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-02-21_to_2023-02-21"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-21</xbrli:startDate> <xbrli:endDate>2023-02-21</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-02-21_to_2023-02-21">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">PURSUANT TO SECTION 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">DATE OF REPORT (Date of earliest event reported): February&#160;22, 2023 (<ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt:datemonthdayyearen">February 21, 2023</ix:nonNumeric>)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">HERON THERAPEUTICS, INC.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in Its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-02-21_to_2023-02-21">001-33221</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-02-21_to_2023-02-21">94-2875566</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation or Organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br />Identification No.)</span></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-02-21_to_2023-02-21">4242 Campus Point Court</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-02-21_to_2023-02-21">Suite 200</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-02-21_to_2023-02-21">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-02-21_to_2023-02-21">92121</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-02-21_to_2023-02-21">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-02-21_to_2023-02-21">251-4400</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-02-21_to_2023-02-21">Common Stock, par value $0.01 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-02-21_to_2023-02-21">HRTX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR <span style="white-space:nowrap">&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-02-21_to_2023-02-21" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;21, 2023, Heron Therapeutics, Inc. (the &#8220;Company&#8221;) entered into a Cooperation Agreement (the &#8220;Cooperation Agreement&#8221;) with Rubric Capital Management LP and the persons and entities listed on Schedule A thereto (collectively, &#8220;Rubric&#8221;), Velan Capital Investment Management LP and the persons and entities listed on Schedule B thereto (collectively, &#8220;Velan&#8221; and, together with Rubric, the &#8220;Investor Group&#8221;) regarding certain changes to the composition of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and other related matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Cooperation Agreement, the Company has agreed to: (1)&#160;increase the size of the Board from seven to eight directors (and fix the size of the Board at such size during the Cooperation Period (as defined below)); (2) appoint Adam Morgan and Craig Collard (the &#8220;Investor Group Appointees&#8221;) and Kevin Kotler (collectively with the Investor Group Appointees, the &#8220;New Directors&#8221;) to serve as directors of the Company; (3)&#160;cause Mr.&#160;Morgan to be appointed to the Nominating&#160;&amp; Corporate Governance Committee, Mr.&#160;Collard to be appointed to the Compensation Committee and Mr.&#160;Kotler to be appointed to the Audit Committee and Compensation Committee; and (4)&#160;include the New Directors in the Company&#8217;s slate of nominees for the election of directors at the Company&#8217;s 2023 annual meeting of stockholders (the &#8220;2023 Annual Meeting&#8221;) and recommend that the Company&#8217;s stockholders vote in favor of their election at the 2023 Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the conclusion of the 2023 Annual Meeting, the Company has agreed to separate the positions of Chairman of the Board and Chief Executive Officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cooperation Agreement further provides that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if Velan&#8217;s ownership level falls below the lesser of (x) 3.5% of the Company&#8217;s outstanding shares of common stock, par value $0.01 per share, and (y) 4,161,084 shares of common stock, Mr.&#160;Morgan will immediately resign from the Board; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, following the date of the Cooperation Agreement, any Investor Group Appointee is unable or unwilling to serve as a director for any reason, the Investor Group will be able to suggest a substitute person to replace such person (a &#8220;Replacement Director&#8221;). The Investor Group&#8217;s ability to suggest a Replacement Director is conditioned upon the Investor Group&#8217;s aggregate beneficial ownership not being less than the lesser of (x) 6.8% of the Company&#8217;s outstanding shares of common stock and (y) 8,125,000 shares of common stock. Further, the ultimate appointment of any Replacement Director is subject to the Board&#8217;s determination that such Replacement Director is reasonably acceptable. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cooperation Agreement includes certain voting commitments, standstill, and mutual <span style="white-space:nowrap">non-disparagement</span> provisions (subject to certain carveouts and exceptions) that generally remain in place during the period beginning upon the execution and delivery of the Cooperation Agreement and ending 30 days prior to the nomination deadline for the Company&#8217;s 2024 annual meeting of stockholders (the &#8220;2024 Annual Meeting&#8221;) (such date, the &#8220;Initial Trigger Date&#8221; and, such period, the &#8220;Cooperation Period&#8221;). The Cooperation Period will be extended until the date that is 30 days prior to the nomination deadline for the Company&#8217;s 2025 annual meeting of stockholders if: (A)&#160;the Company notifies the Investor Group and the Investor Group Appointees in writing at least 10 days prior to the Initial Trigger Date that the Board irrevocably offers to nominate each of the Investor Group Appointees for election at the 2024 Annual Meeting and (B)&#160;the Investor Group and the Investor Group Appointees agree to such nomination within 10 days of receipt of such notice. If the Investor Group does not accept such renomination within such <span style="white-space:nowrap">10-day</span> period, then the Cooperation Period will terminate as scheduled and each Investor Group Appointee will resign from the Board if the Investor Group delivers a notice of an intent to nominate directors for election at the 2024 Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Cooperation Agreement filed as Exhibit 10.1 hereto. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The information set forth in Item 1.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> is incorporated into this Item 5.02 by reference. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Cooperation Agreement, effective on February&#160;21, 2023, the Board increased the size of the Board from seven to eight directors and appointed Adam Morgan, Craig Collard, and Kevin Kotler to the Board. In addition, also effective on February&#160;21, 2023, Mr.&#160;Morgan will join the Nominating&#160;&amp; Corporate Governance Committee, Mr.&#160;Collard will join the Compensation Committee and Mr.&#160;Kotler will join the Audit Committee and Compensation Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For their service as <span style="white-space:nowrap">non-employee</span> directors of the Company, Mr.&#160;Morgan, Mr.&#160;Collard and Mr.&#160;Kotler will receive compensation in accordance with the Company&#8217;s standard compensation program for its <span style="white-space:nowrap">non-employee</span> directors, which is described under the heading &#8220;Director Compensation&#8221; in the Company&#8217;s definitive proxy statement on Schedule 14A filed with the United States Securities and Exchange Commission on April&#160;25, 2022. Mr.&#160;Morgan, Mr.&#160;Collard and Mr.&#160;Kotler will also enter into the Company&#8217;s standard indemnification agreement with directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no related party transactions between the Company and Adam Morgan, Craig Collard, or Kevin Kotler that would require disclosure under Item 404(a) of Regulation <span style="white-space:nowrap">S-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Directors Stephen Davis and Kimberly Manhard resigned as members of the Board effective February&#160;21, 2023. Neither of Mr.&#160;Davis&#8217;s nor Ms.&#160;Manhard&#8217;s resignations was a result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies or practices. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;22, 2023, the Company issued a press release with respect to the matters described in this Current Report on Form <span style="white-space:nowrap">8-K</span> and such press release is attached hereto and furnished as Exhibit 99.1. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d457589dex101.htm">Cooperation Agreement, dated February&#160;21, 2023, by and among Heron Therapeutics, Inc., Rubric Capital Management LP, the persons and entities listed on Schedule A thereto, Velan Capital Investment Management LP, and the persons and entities listed on Schedule B thereto </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d457589dex991.htm">Press Release, dated February&#160;22, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The cover page from this Current Report on Form <span style="white-space:nowrap">8-K,</span> formatted in Inline XBRL</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: February 22, 2023 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">HERON THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Szekeres</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">David Szekeres</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President, Chief Operating Officer</td></tr>
</table></div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d457589dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COOPERATION AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Cooperation Agreement, dated as of February 21, 2023 (this &#147;<U>Agreement</U>&#148;), is made by and among Heron Therapeutics, Inc.,
a Delaware corporation (the &#147;<U>Company</U>&#148;), Rubric Capital Management LP, a Delaware limited partnership (and collectively with the other persons and entities listed on <U>Schedule A</U> hereto, &#147;<U>Rubric</U>&#148;), and Velan
Capital Investment Management LP, a Delaware limited partnership (and collectively with the other persons and entities listed on <U>Schedule B</U> hereto, &#147;<U>Velan</U>&#148; and, together with Rubric, the &#147;<U>Investor Group</U>,&#148;
and, for clarity and as applicable, including each member thereof acting individually). The Company and each member of the Investor Group are collectively herein referred to as the &#147;<U>Parties</U>&#148; and individually as a
&#147;<U>Party</U>.&#148; Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in <U>Section</U><U></U><U>&nbsp;22</U> below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>RECITALS </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
the Company and the Investor Group have engaged in various discussions and communications concerning the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Company and the Investor Group have determined to come to an agreement with respect to certain matters relating to the composition of the Board of Directors of the Company (the &#147;<U>Board</U>&#148;) and certain other matters, as provided in this
Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants and agreements contained herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound hereby, agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;1. <U>Board Composition and Related Agreements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Board Composition</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Within five (5)&nbsp;Business Days following the execution of this Agreement, the Board and all applicable committees of the Board shall
take all necessary actions to (x)&nbsp;fix the size of the Board at eight (8)&nbsp;directors, (y) appoint each of Adam Morgan (the <U>&#147;Velan Principal Appointee</U>&#148;) and Craig A. Collard (the &#147;<U>Investor Group Independent
Appointee</U>,&#148; and each of the Velan Principal Appointee and the Investor Group Independent Appointee is referred to as an &#147;<U>Investor Group Appointee</U>&#148; and, collectively, the &#147;<U>Investor Group Appointees</U>&#148;) as a
director of the Company and (z)&nbsp;appoint Kevin Kotler (the &#147;<U>New Independent Appointee</U>&#148; and, collectively with the Investor Group Appointees, the &#147;<U>New Directors</U>&#148;) as a director of the Company. During the period
commencing with the date of this Agreement through the expiration of the Cooperation Period, the Board and all applicable committees of the Board shall not increase the size of the Board to more than eight (8)&nbsp;directors, unless mutually agreed
to in writing by the Company and the Investor Group. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Concurrent with the execution of this Agreement, each Investor Group Appointee will
execute and deliver to the Company an irrevocable letter of resignation in the form attached hereto as <U>Exhibit A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) At all
times while serving as a member of the Board, the New Directors shall comply with the same policies and obligations regarding confidentiality, conflicts of interest, related party transactions, fiduciary duties, codes of conduct, insider trading and
disclosure policies, director resignation policy, and other governance guidelines and policies of the Company applicable to all other <FONT STYLE="white-space:nowrap">non-management</FONT> members of the Board (such policies, the &#147;<U>Company
Policies</U>&#148;). The Company represents and warrants that all Company Policies currently in effect are publicly available on the Company&#146;s website or have been provided to the Investor Group or its counsel. The Company agrees that, upon
appointment to the Board, each New Director shall receive (i)&nbsp;the same benefits of director and officer insurance as all other <FONT STYLE="white-space:nowrap">non-management</FONT> directors on the Board, (ii)&nbsp;the same compensation for
his or her service as a director as the compensation received by other <FONT STYLE="white-space:nowrap">non-management</FONT> directors on the Board and (iii)&nbsp;such other benefits on the same basis as all other
<FONT STYLE="white-space:nowrap">non-management</FONT> directors on the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>New Director Nominations</U>. The Company&#146;s
slate of nominees for the election of directors of the Company at the Company&#146;s 2023 annual meeting of stockholders (the &#147;<U>2023 Annual Meeting</U>&#148;) shall include the New Directors and no more than five (5)&nbsp;other persons as
nominees. The Company shall recommend, support and solicit proxies in favor of the election of the New Directors at the 2023 Annual Meeting in the same manner as it recommends, supports and solicits proxies in favor of the election of the
Company&#146;s other nominees at the 2023 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Other Board Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Following their appointments to the Board and until the expiration of the Cooperation Period, each New Director shall be appointed to and
serve on the following committees of the Board (subject to such person&#146;s continued willingness to serve on such committees): (x) the Velan Principal Appointee &#150; the Nominating and Corporate Governance Committee of the Board (the
&#147;<U>Nominating Committee</U>&#148;), (y) the Investor Group Independent Appointee&#151;the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;) and (z)&nbsp;the New Independent Appointee&#151;the Audit Committee
of the Board and the Compensation Committee. Without limiting the foregoing, the Board shall, in accordance with its customary governance processes, give each New Director the same due consideration for membership to any committee of the Board as
any other independent director with similar relevant expertise and qualifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Immediately following the conclusion of the 2023
Annual Meeting, the Board shall appoint the Investor Group Independent Appointee as the Chairman of the Board, subject to the reasonable approval of the Board (such approval not to be unreasonably withheld). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Within ten (10)&nbsp;Business Days after the execution of this Agreement, the Board shall form a working group of directors (that shall
include the New </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Directors) focused on evaluating potential value creation and operational and financial initiatives for the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Replacement Directors</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Following the date of this Agreement, if any Investor Group Appointee is unable or unwilling to serve as a director for any reason, then
the Investor Group shall have the ability within thirty (30)&nbsp;days of such Investor Group Appointee&#146;s departure from the Board to recommend a substitute person to replace such Investor Group Appointee, in accordance with, and subject to,
this <U>Section</U><U></U><U>&nbsp;1(d)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Except as otherwise specified in this Agreement, if a replacement Director (a
&#147;<U>Replacement Director</U>&#148;) is appointed to the Board pursuant to this <U>Section</U><U></U><U>&nbsp;1(d)</U>, all references in this Agreement to the terms &#147;Investor Group Appointee,&#148; &#147;Investor Group Appointees,&#148;
&#147;Investor Group Independent Appointee&#148; or &#147;Velan Principal Appointee&#148; will include such Replacement Director(s), as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The appointment of any Replacement Director shall be subject to (A)&nbsp;the execution and delivery by such Replacement Director of
(x)&nbsp;a fully completed copy of the Company&#146;s standard director and officer questionnaire and other reasonable and customary director onboarding documentation required by the Company in connection with the appointment or election of all new <FONT
STYLE="white-space:nowrap">non-management</FONT> Board members, (y)&nbsp;a written acknowledgment that such Replacement Director agrees to be bound by all Company Policies and (z)&nbsp;the Replacement Director Irrevocable Letter of Resignation in
the form attached as <U>Exhibit B</U> hereto, (B)&nbsp;such Replacement Director qualifying as &#147;independent&#148; pursuant to SEC rules and regulations and applicable stock exchange listing standards, (C)&nbsp;in the case of a Replacement
Director for the Investor Group Independent Appointee only, such Replacement Director not being a current or former employee or controlled Affiliate of any member of the Investor Group, and (D)&nbsp;the Board determining such Replacement Director to
be reasonably acceptable (such acceptance not to be unreasonably withheld). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) The Nominating Committee, acting reasonably and in good
faith, shall make its determination and recommendation regarding whether any candidate for Replacement Director so qualifies within five (5)&nbsp;Business Days after such candidate has submitted to the Company the documentation required by this
<U>Section</U><U></U><U>&nbsp;1(d)</U>. If the Nominating Committee does not accept a substitute person recommended by the Investor Group as a Replacement Director, then the Investor Group will have the right to recommend additional substitute
person(s) whose appointment will be subject to the Nominating Committee recommending such person in accordance with the procedures described in this <U>Section</U><U></U><U>&nbsp;1(d)</U>. Upon the recommendation of a candidate for Replacement
Director by the Nominating Committee, the Board shall review and vote on the appointment of such candidate to the Board no later than five (5)&nbsp;Business Days after the Nominating Committee&#146;s recommendation of such candidate;
<U>provided</U>, that if the Board does not approve and appoint such candidate for Replacement Director to the Board (such approval not to be unreasonably withheld), the Parties shall continue to follow the procedures described in this
<U>Section</U><U></U><U>&nbsp;1(d)(iv)</U> until a Replacement Director is approved and appointed to the Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) If, at any time following the date of this Agreement, the Investor Group&#146;s
aggregate Beneficial Ownership is less than the lesser of (x) 6.8% of the outstanding shares of Common Stock and (y) 8,125,000 shares of Common Stock (subject to adjustment for stock splits, reclassifications, combinations and similar adjustments)
(the &#147;<U>Investor Group Minimum Ownership Level</U>&#148;), then the Investor Group shall immediately and irrevocably lose its rights under this <U>Section</U><U></U><U>&nbsp;1(d)</U> to recommend or appoint a Replacement Director with respect
to the Investor Group Appointees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Additional Agreements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each member of the Investor Group agrees (A)&nbsp;to cause its controlled Affiliates and Representatives to comply with the terms of this
Agreement and (B)&nbsp;that it shall be responsible for any breach of this Agreement by any such controlled Affiliate. A breach of this Agreement by a controlled Affiliate or Representative of any member of the Investor Group, if such controlled
Affiliate is not a Party hereto, shall be deemed to occur if such controlled Affiliate or Representative engages in conduct that would constitute a breach of this Agreement if such controlled Affiliate or Representative were a Party hereto to the
same extent as the Investor Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) During the Cooperation Period, each member of the Investor Group agrees that it shall, and shall
cause each of its controlled Affiliates to, appear in person or by proxy at each annual or special meeting of the stockholders of the Company (each, a &#147;<U>Stockholder Meeting</U>&#148;) and vote all Voting Securities beneficially owned,
directly or indirectly, by the Investor Group or such controlled Affiliate (or which the Investor Group or such Affiliate has the right or ability to vote) at such meeting (A)&nbsp;in favor of the slate of directors recommended by the Board,
(B)&nbsp;against the election of any nominee for director not approved, recommended and nominated by the Board for election at any such meeting, and (C)&nbsp;in accordance with the Board&#146;s recommendation with respect to any other matter
presented at such meeting; <U>provided</U>, <U>however</U>, that if Institutional Shareholder Services Inc. (&#147;<U>ISS</U>&#148;) and Glass Lewis&nbsp;&amp; Co., LLC (&#147;<U>Glass Lewis</U>&#148;) both make a recommendation that differs from
the recommendation of the Board with respect to any proposal submitted to the Company&#146;s stockholders at any Stockholder Meeting (other than as related to the election or removal of directors), the Investor Group shall be permitted to vote in
accordance with the ISS and Glass Lewis recommendation; <U>provided</U>, <U>further</U>, that the Investor Group shall be permitted to vote in its sole discretion with respect to any proposals relating to an Extraordinary Transaction that requires a
vote of the Company&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) During the Cooperation Period, (a)&nbsp;the Investor Group will notify the Company within
two (2)&nbsp;Business Days of such time as the Investor Group in the aggregate Beneficially Owns less than the Investor Group Minimum Ownership Level and (b)&nbsp;Velan will notify the Company within (2)&nbsp;Business Days of such time as Velan in
the aggregate Beneficially Owns less than the lesser of (x) 3.5% of the outstanding shares of Common Stock and (y) 4,161,084 shares of Common Stock (subject to adjustment for stock splits, reclassifications, combinations and similar adjustments)
(the &#147;<U>Velan Minimum Ownership Level</U>&#148;). Such information provided to the Company will be kept strictly confidential unless required to be disclosed pursuant to law, legal process, subpoena, the rules of any stock exchange
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any legal requirement or as part of a response to a request for information from any governmental authority with jurisdiction over the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Standstill Provisions</U>. During the Cooperation Period, each member of the Investor Group shall not, and shall cause each
of its controlled Affiliates not to, directly or indirectly, alone or in concert with others (including through any Representative of any member of the Investor Group or any of its controlled Affiliates): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) acquire, cause to be acquired, or offer, seek or agree to acquire, whether by purchase, tender or exchange offer, through the
acquisition of control of another person, by joining or forming a partnership, limited partnership, syndicate or other group (including any group of persons that would be treated as a single &#147;person&#148; under Section&nbsp;13(d) of the
Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the &#147;<U>Exchange Act</U>&#148;)), through swap or hedging transactions or otherwise (the taking of any such action, an
&#147;<U>Acquisition</U>&#148;), Beneficial Ownership of any securities or assets of the Company (or any direct or indirect rights or options to acquire such ownership, including voting rights decoupled from the underlying Voting Securities) such
that after giving effect to any such Acquisition, the Investor Group or any of its controlled Affiliates holds, directly or indirectly, an aggregate Beneficial Ownership in excess of 15.0% of the then outstanding Voting Securities; <U>provided</U>,
<U>however</U>, to the extent the group under Section&nbsp;13(d) of the Exchange Act consisting of the members of the Investor Group is terminated, Rubric and Velan&#146;s aggregate Beneficial Ownership shall not exceed 15.0%, or (ii)&nbsp;effect or
seek to effect, offer or propose to effect, cause or participate in, or in any way assist, knowingly facilitate or knowingly encourage any other Person to effect or seek, offer or propose to effect or participate in an Extraordinary Transaction (but
nothing in this <U>Section</U><U></U><U>&nbsp;2(a)</U> shall prohibit any member of the Investor Group or any of its controlled Affiliates from tendering into (or failing to tender into) a tender or exchange offer, receiving payment or other
consideration for securities of the Company, voting its Voting Securities &#147;for&#148; or &#147;against&#148; any Extraordinary Transaction, or otherwise participating in any such transaction on the same basis as other stockholders of the
Company, or from participating in any such transaction that has been approved by the Board); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) (i) nominate, give notice of an intent
to nominate, or recommend for nomination a person for election to the Board (other than pursuant to <U>Section</U><U></U><U>&nbsp;1</U>) or take any action in respect of the removal of any director, (ii)&nbsp;knowingly seek or knowingly encourage
any person to submit any nomination in furtherance of a &#147;contested solicitation&#148; or take any other action in respect of the election or removal of any director, (iii)&nbsp;submit, or knowingly seek or knowingly encourage the submission of,
any stockholder proposal (pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8</FONT> or otherwise) for consideration at, or bring any other business before, any Stockholder Meeting, (iv)&nbsp;request, or knowingly initiate, knowingly encourage
or participate in any request, to call a Stockholder Meeting, (v)&nbsp;seek to amend any provision of the Company&#146;s Certificate of Incorporation, as amended, or Amended and Restated Bylaws (the &#147;<U>Bylaws</U>&#148;), or (vi)&nbsp;take any
action similar to the foregoing with respect to any subsidiary of the Company; <U>provided</U>, <U>however</U>, that nothing in this Agreement shall prevent the Investor Group or its controlled Affiliates from taking actions in furtherance of
identifying director candidates in connection with the 2024 Annual Meeting if the Cooperation Period expires on the Initial Trigger Date, or the 2025 Annual Meeting if the Cooperation Period expires on the Second Trigger Date, so long as such
actions do not create a public disclosure obligation for the Investor Group or the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and are undertaken on a basis reasonably designed to be confidential and in accordance in all material respects with any member of the Investor Group&#146;s normal practices in the circumstances;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) solicit any proxy, consent or other authority to vote of stockholders or conduct any other referendum (binding or <FONT
STYLE="white-space:nowrap">non-binding)</FONT> (including any &#147;withhold,&#148; &#147;vote no&#148; or similar campaign) with respect to, or from the holders of, Voting Securities, or become a &#147;participant&#148; (as such term is defined in
Instruction 3 to Item 4 of Schedule 14A promulgated under the Exchange Act) in, or knowingly assist, advise, initiate, knowingly encourage or knowingly influence any person (other than the Company) in, any &#147;solicitation&#148; of any proxy,
consent or other authority to vote any Voting Securities (other than such assistance, advice, encouragement or influence that is consistent with the Board&#146;s recommendation in connection with such matter);<I> </I><U>provided</U>, <U>however</U>,
that the foregoing shall not restrict any member of the Investor Group from stating how it intends to vote with respect to an Extraordinary Transaction, if any, in accordance with <U>Section</U><U></U><U>&nbsp;1(e)(ii)</U> and the reasons therefor;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) (i) grant any proxy, consent or other authority to vote with respect to any matters (other than to the named proxies included in the
Company&#146;s proxy card for any Stockholder Meeting) or (ii)&nbsp;deposit or agree or propose to deposit any securities of the Company in any voting trust or similar arrangement, or subject any securities of the Company to any agreement or
arrangement with respect to the voting of such securities (including a voting agreement or pooling arrangement), other than (A)&nbsp;any such voting trust or arrangement solely for the purpose of delivering to the Company or its designee a proxy,
consent, or other authority to vote in connection with a solicitation made by or on behalf of the Company or (B)&nbsp;customary brokerage accounts, margin accounts and prime brokerage accounts; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) knowingly encourage, advise or knowingly influence any person, or knowingly assist any person in so knowingly encouraging, advising or
knowingly influencing any person, with respect to the giving or withholding of any proxy, consent or authority to vote any Voting Securities or in conducting any referendum (binding or <FONT STYLE="white-space:nowrap">non-binding)</FONT> (including
any &#147;withhold,&#148; &#147;vote no&#148; or similar campaign); <U>provided</U>, <U>however</U>, that the foregoing shall not restrict any member of the Investor Group from stating how it intends to vote with respect to an Extraordinary
Transaction, if any, in accordance with <U>Section</U><U></U><U>&nbsp;1(e)(ii)</U> and the reasons therefor; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) form, join, knowingly
encourage the formation of, or in any way participate in any partnership, limited partnership, syndicate or group (within the meaning of Section&nbsp;13(d)(3) of the Exchange Act) with respect to any Voting Securities (other than a group that
includes all or some of the members of the Investor Group, but does not include any other entities or persons that are not members of the Investor Group as of the date hereof; <U>provided</U>, <U>however</U>, that nothing herein shall limit the
ability of a controlled Affiliate of the Investor Group to join such group following the execution of this Agreement, so long as any such controlled Affiliate agrees to be bound by the terms and conditions of this Agreement); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) publicly make or publicly advance any request or proposal to amend, modify or waive any provision of this Agreement, or take any action
challenging the validity or enforceability of any provision of or obligation arising under this Agreement; <U>provided</U>, that the Investor Group may make confidential requests to the Board to amend, modify or waive any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provision of this Agreement, which the Board may accept or reject in its sole and absolute discretion (it being understood and agreed that the Board shall consider in good faith any waiver
requests to the Acquisition limits set forth in <U>Section</U><U></U><U>&nbsp;2(a)</U> in the event of any registered securities offerings made by the Company), so long as any such request is not publicly disclosed by the Investor Group and is made
by the Investor Group in a manner that could not reasonably be expected to require, and that does not require, the public disclosure thereof by the Company, the Investor Group or any other person; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) make a request for a list of the Company&#146;s stockholders or for any books and records of the Company whether pursuant to
Section&nbsp;220 of the Delaware General Corporation Law or otherwise; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) enter into any discussion, negotiation, agreement,
arrangement or understanding concerning any of the foregoing (other than this Agreement) or knowingly encourage, assist, solicit, seek or seek to cause any person to undertake any action inconsistent with this <U>Section</U><U></U><U>&nbsp;2</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained in <U>Section</U><U></U><U>&nbsp;2</U> or elsewhere in this Agreement, the members of the Investor
Group shall not be prohibited or restricted from communicating privately with the Chief Executive Officer of the Company, the Board or any director of the Company regarding any matter, so long as such communications are not intended to, and would
not reasonably be expected to, require any public disclosure of such communications by any Party. Further, no Party shall be prohibited from taking any action necessary to comply with any law, rule or regulation or any action required by any
governmental or regulatory authority or stock exchange that has, or may have, jurisdiction over such Party, <U>provided</U> that a breach by such Party of this Agreement is not the cause of the applicable requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, for the avoidance of doubt, notwithstanding anything in this Agreement to the contrary, nothing in this Agreement shall be deemed to limit the
exercise in good faith by any New Director (or a Replacement Director) of such person&#146;s fiduciary duties solely in such person&#146;s capacity as a director of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Representations and Warranties of All Parties</U>. Each Party represents and warrants to the other Parties that
(a)&nbsp;such Party has all requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder, (b)&nbsp;this Agreement has been duly and validly authorized, executed and delivered by it and is a valid and
binding obligation of such Party, enforceable against such Party in accordance with its terms (subject to applicable bankruptcy and similar laws relating to creditors&#146; rights and to general equity principles) and (c)&nbsp;this Agreement will
not result in a material violation of any (i)&nbsp;term or condition of any agreement to which such person is a party or by which such Party may otherwise be bound or (ii)&nbsp;law, rule, license, regulation, judgment, order or decree governing or
affecting such Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Representations and Warranties of the Investor Group</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Rubric represents, warrants and covenants to the Company that, as of the date of this Agreement, Rubric and its Affiliates and/or managed
funds collectively beneficially own and are entitled to vote an aggregate of 11,750,000 shares of Common Stock and does not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have any Synthetic Position (other than the shares of Common Stock Beneficially Owned as set forth in this <U>Section</U><U></U><U>&nbsp;4(a)</U>) in any Voting Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Velan represents, warrants and covenants to the Company that, as of the date of this Agreement, Velan and its Affiliates and/or managed
funds collectively beneficially own and are entitled to vote on an aggregate of 4,500,000 shares of Common Stock and does not have any Synthetic Position (other than the shares of Common Stock Beneficially Owned as set forth in this
<U>Section</U><U></U><U>&nbsp;4(b)</U>) in any Voting Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Each member of the Investor Group represents, warrants and
covenants to the Company that no member of the Investor Group is or will become party to any agreement, arrangement or understanding (whether written or oral) with the Investor Group Appointees or any Replacement Director with respect to such
person&#146;s service as a director on the Board, including any such agreement, arrangement or understanding with respect to how such person should or would vote or act on any issue or question as a director. For the avoidance of doubt, the Velan
Principal Appointee (and any potential Replacement Director affiliated with Velan that is appointed to fill a vacancy caused by the Velan Principal Appointee ceasing to serve on the Board) may receive compensation from Velan in connection with such
person&#146;s employment thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Press Release; Communications</U>. Promptly following the execution of this
Agreement, the Company shall issue a mutually agreeable press release in the form attached hereto as <U>Exhibit C</U> (the &#147;<U>Press Release</U>&#148;) announcing certain terms of this Agreement. During the Cooperation Period and subject to the
terms of this Agreement, neither the Company (including the Board or any committee thereof) nor the Investor Group shall make or cause to be made, and the Company and the Investor Group will cause their respective controlled Affiliates not to make
or cause to be made, any public announcement or statement with respect to the subject matter of this Agreement that is inconsistent with or contrary to the terms of this Agreement without the prior written consent of the other Party. The Company
acknowledges and agrees that the Investor Group may file this Agreement as an exhibit to its Schedule 13D. The Company shall be given a reasonable opportunity to review and comment on any Schedule 13D filing made by the Investor Group (including any
separate filings made by individual members thereto) with respect to this Agreement, and the Investor Group shall give reasonable consideration to any comments of the Company. The Investor Group acknowledges and agrees that the Company may file this
Agreement and file or furnish the Press Release with the SEC as exhibits to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and other filings with the SEC. The Investor Group shall be given a reasonable opportunity to review and
comment on any Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other filing with the SEC made by the Company with respect to this Agreement, and the Company shall give reasonable consideration to any comments of the Investor
Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Expenses</U>. Each Party shall be responsible for its own fees and expenses incurred in connection with the
negotiation, execution and effectuation of this Agreement and the transactions contemplated hereby; except that the Company will reimburse the Investor Group for its reasonable, documented <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with seeking representation on the Board and the negotiation and entry into this Agreement, in an amount not to exceed $150,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Confidentiality</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Investor Group Appointees shall be required to preserve the confidentiality of the Company&#146;s business and information, including
any <FONT STYLE="white-space:nowrap">non-public</FONT> information entrusted to or obtained by such director by reason of his or her position as a director of the Company (&#147;<U>Confidential Information</U>&#148;). The term Confidential
Information does not include does not include any information that (i)&nbsp;was publicly known and made generally available in the public domain prior to the time of disclosure to the receiving party by or on behalf of the Company; (ii)&nbsp;becomes
publicly known and made generally available after disclosure to the receiving party by or on behalf of the Company through no action or inaction of the receiving party; (iii)&nbsp;is already in the possession of the receiving party at the time of
disclosure by or on behalf of the Company, other than as a result of a breach of the terms of this Agreement by any Investor Group Appointee or any member of the Investor Group; (iv)&nbsp;is obtained by the receiving party from a third party not
under confidentiality obligations to the Company and without a breach of any obligations of confidentiality to the Company; or (v)&nbsp;is independently developed by the receiving party without use of or reference to the Company&#146;s information
entrusted to such person by reason of his or her position as a director of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the foregoing, the Velan
Principal Appointee (or any Replacement Director appointed to fill the Velan Principal Appointee&#146;s seat on the Board who is a Velan Investment Professional) may provide Confidential Information to the investment professionals of Velan
(&#147;<U>Velan Investment Professionals</U>&#148;), solely to the extent such Velan Investment Professionals need to know such information in connection with Velan&#146;s investment in the Company; <U>provided</U>, <U>however</U>, that Velan
(i)&nbsp;shall inform each such Velan Investment Professional of the confidential nature of the Confidential Information, (ii)&nbsp;shall cause each such Velan Investment Professional not to disclose any Confidential Information to any Person other
than to a Velan Investment Professional in compliance with this <U>Section</U><U></U><U>&nbsp;7</U> and (iii)&nbsp;shall cause each Velan Investment Professional not to use any Confidential Information other than in connection with Velan&#146;s
investment in the Company. Velan shall be responsible for the breach of this <U>Section</U><U></U><U>&nbsp;7</U> by any of its controlled Affiliates. For the avoidance of doubt, no other member of the Board (including the Investor Group Independent
Appointee) shall be permitted to provide Confidential Information to Velan or any other Party outside of the Company without the express advance written consent from the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything in this Agreement to the contrary, in the event that Velan is required in connection with any legal requirement
(excluding any such requirement arising out of any action or proceeding initiated by Velan, including for the avoidance of doubt any requirement to make a filing with the SEC or under any securities laws or regulations) to disclose Confidential
Information, it is agreed that Velan will, to the extent legally permissible, provide the Company with prompt written notice of such event so that the Company may seek a protective order or other appropriate remedy (at the Company&#146;s sole
expense) or waive compliance with the applicable provisions of this Agreement. In the event that (i)&nbsp;such protective order or other remedy is not obtained and disclosure of Confidential Information is therefore required (and such requirement
does not arise from a breach of this Agreement by Velan) or (ii)&nbsp;the Company consents in writing to having the Confidential Information produced or disclosed pursuant to such legal requirement, Velan (A)&nbsp;may, without liability hereunder,
furnish that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
portion (and only that portion) of the Confidential Information that Velan&#146;s legal counsel advises is legally required to be disclosed and (B)&nbsp;will use reasonable efforts, at the
Company&#146;s sole expense, to obtain reasonable assurance that confidential treatment is accorded to any Confidential Information so furnished. In no event will Velan oppose any action by the Company to obtain a protective order or other relief to
prevent the disclosure of the Confidential Information or to obtain reliable assurance that confidential treatment will be afforded to the Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any confidentiality obligations under this <U>Section</U><U></U><U>&nbsp;7</U> shall expire eighteen (18)&nbsp;months after the date on
which the Velan Principal Appointee no longer serves as a director of the Company; <U>provided</U>, that Velan shall maintain in accordance with the confidentiality obligations set forth herein any Confidential Information constituting trade secrets
for such longer time as such information constitutes a trade secret of the Company as defined under 18 U.S.C. &#167; 1839(3). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>Securities Laws</U>. Velan acknowledges that it is aware, and will advise each Velan Investment Professional who receives
Confidential Information pursuant to <U>Section</U><U></U><U>&nbsp;7(b)</U>, that United States securities laws prohibit any Person who has received material, <FONT STYLE="white-space:nowrap">non-public</FONT> information from purchasing or selling
securities on the basis of such information or from communicating such information to any other Person under circumstances in which it is reasonably foreseeable that such Person may trade securities on the basis of such information. Velan agrees
that neither it nor the Velan Investment Professionals will use or communicate any Confidential Information in violation of such laws. Velan maintains customary policies and procedures designed to prevent unauthorized disclosure and use of material,
<FONT STYLE="white-space:nowrap">non-public</FONT> information. During the Cooperation Period, the Company shall provide Velan with at least two (2)&nbsp;Business Days advance written notice of each opening and expiration of each blackout period,
and Velan shall not purchase or sell, directly or indirectly, any securities of the Company during any blackout periods applicable to all directors under the Company&#146;s insider trading policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U><FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U>. Each of the Parties covenants and agrees that, during the
Cooperation Period, neither it nor any of its respective controlled Affiliates, Representatives, or any of its or its controlled Affiliates&#146; Representatives, successors or assigns shall in any way publicly (or in any way reasonably expected to
be made public) disparage, comment negatively upon, slander, criticize, attempt to discredit, call into disrepute, defame or otherwise make or cause to be made any public statements or statements reasonably expected to be made public that would
reasonably be expected to damage the business or reputation of the other Party or such other Party&#146;s subsidiaries, controlled Affiliates, officers (including any current or former officer of a Party or a Party&#146;s subsidiaries), directors
(including any current or former director of a Party or a Party&#146;s subsidiaries) or employees or any of their businesses, products or services. Each Party shall use its commercially reasonable efforts to cause its and its controlled
Affiliates&#146; Representatives to comply with this <U>Section</U><U></U><U>&nbsp;9</U>. Nothing in this <U>Section</U><U></U><U>&nbsp;9</U> will be deemed to prevent either the Company or the Investor Group from complying with its respective
disclosure obligations under law, legal process, subpoena, the rules of any stock exchange or any legal requirement or as part of a response to a request for information from any governmental authority with jurisdiction over the Party from whom
information is sought. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Termination</U>. Unless otherwise mutually agreed in writing by each
Party, this Agreement shall terminate on the earlier of (i)&nbsp;the expiration of the Cooperation Period and (ii)&nbsp;a Change of Control of the Company. Notwithstanding the foregoing, <U>Sections</U> <U>6</U> and <U>10</U> through <U>22</U> shall
survive the termination or expiration of this Agreement, and <U>Section</U><U></U><U>&nbsp;7</U> shall survive in accordance with the terms set forth therein. No termination of this Agreement shall relieve any Party from liability for any breach of
this Agreement prior to such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <U>Severability</U>. If any term, provision, covenant or restriction of this
Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected,
impaired or invalidated. Each Party agrees to use its commercially reasonable best efforts to agree upon and substitute a valid and enforceable term, provision, covenant or restriction for any of such that is held invalid, void or unenforceable by a
court of competent jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. <U>Notices</U>. Any notices, consents, determinations, waivers or other communications
required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered (i)&nbsp;upon receipt, when delivered personally, (ii)&nbsp;upon confirmation of receipt, when sent by <FONT
STYLE="white-space:nowrap">e-mail</FONT> (<U>provided</U>, that such confirmation is not automatically generated), or (iii)&nbsp;one (1) Business Day after deposit with a nationally recognized overnight delivery service, in each case properly
addressed to the Party to receive the same. The addresses for such communications shall be: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If to the Company</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">4242
Campus Point Court, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">San Diego, California 92121 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;David Szekeres, EVP, Chief Operating Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dszekeres@herontx.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice) to</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York,
New York 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Daniel E. Wolf, P.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shaun J. Mathew,
P.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;daniel.wolf@kirkland.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shaun.mathew@kirkland.com </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>If to the Investor Group</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o Rubric Capital Management LP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">155 East 44th St, Suite 1630 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New
York, New York 10017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">
Attention: &nbsp;&nbsp;&nbsp;&nbsp;Brian Kleinhaus, Chief Compliance Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;brian@rubriccapital.com</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">c/o Velan Capital
Investment Management LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1055b Powers Place </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Alpharetta, Georgia 30009 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: &nbsp;&nbsp;&nbsp;&nbsp;Adam Morgan, Chief Investment Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;adam@velancapital.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>with a copy (which shall not constitute notice) to</I>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Olshan Frome Wolosky LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1325
Avenue of the Americas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention:&nbsp;&nbsp;&nbsp;&nbsp;Ryan Nebel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bachar Mahmoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;rnebel@olshanlaw.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;bmahmoud@olshanlaw.com
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <U>Injunctive Relief; Fees</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Party acknowledges and agrees that any breach of any provision of this Agreement shall cause the other Party irreparable harm which
would not be adequately compensable by money damages. Accordingly, in the event of a breach or threatened breach by a Party of any provision of this Agreement, the other Party shall be entitled to seek the remedies of injunction or other preliminary
or equitable relief, without having to prove irreparable harm or actual damages or post a bond or other security. The foregoing right shall be in addition to such other rights or remedies that may be available to the
<FONT STYLE="white-space:nowrap">non-breaching</FONT> Party for such breach or threatened breach, including the recovery of money damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If a Party institutes any legal suit, action, or proceeding against the other Party to enforce this Agreement (or obtain any other remedy
regarding any breach of this Agreement) or arising out of or relating to this Agreement, including contract, equity, tort, fraud, and statutory claims, the prevailing Party in the suit, action, or proceeding is entitled to receive, and the <FONT
STYLE="white-space:nowrap">non-prevailing</FONT> Party shall pay, in addition to all other remedies to which the prevailing Party may be entitled, the costs and expenses incurred by the prevailing Party in conducting the suit, action, or proceeding,
including actual attorneys&#146; fees and expenses, even if not recoverable by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <U>Governing Law; Jurisdiction; Jury
Waiver</U>. This Agreement and all actions, proceedings or counterclaims (whether based on contract, tort or otherwise) arising out of or relating to this Agreement or any action of the Company or the Investor Group in the negotiation,
administration, performance or enforcement hereof shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without giving effect to any choice or conflict of laws provision or rule (whether of the State of
Delaware or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
State of Delaware. Each Party irrevocably agrees that any legal action or proceeding with respect to this Agreement and any rights and obligations arising hereunder, or for recognition and
enforcement of any judgment in respect of this Agreement and any rights and obligations arising hereunder brought by the other Party or its successors or assigns, shall be brought and determined exclusively in the Delaware Court of Chancery and any
state appellate court therefrom within the State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any federal court within the State of Delaware) (the &#147;<U>Chosen Courts</U>&#148;).
Each Party hereby irrevocably submits with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the Chosen Courts and agrees that it will not bring any
action relating to this Agreement in any court other than the Chosen Courts. Each Party hereby irrevocably waives, and agrees not to assert in any action or proceeding with respect to this Agreement, (a)&nbsp;any claim that it is not personally
subject to the jurisdiction of the Chosen Courts for any reason, (b)&nbsp;any claim that it or its property is exempt or immune from jurisdiction of any Chosen Court or from any legal process commenced in the Chosen Courts (whether through service
of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c)&nbsp;to the fullest extent permitted by applicable legal requirements, any claim that (i)&nbsp;the suit, action or
proceeding in any Chosen Court is brought in an inconvenient forum, (ii)&nbsp;the venue of such suit, action or proceeding is improper or (iii)&nbsp;this Agreement, or the subject matter hereof, may not be enforced in or by the Chosen Courts. EACH
PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;15. <U>Counterparts; Electronic Transmission</U>. This Agreement may be executed in two or more counterparts, which together
shall constitute a single agreement. Any signature to this Agreement transmitted by facsimile transmission, by electronic mail in &#147;portable document format&#148; (&#147;.pdf&#148;) form or by any other electronic means intended to preserve the
original graphic and pictorial appearance of a document, shall have the same effect as physical delivery of the paper document bearing the original signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16. <U>No Waiver</U>. Any waiver by any Party of a breach of any provision of this Agreement shall not operate as or be construed
to be a waiver of any other breach of such provision or of any breach of any other provision of this Agreement. The failure of a Party to insist upon strict adherence to any term of this Agreement on one or more occasions shall not be considered a
waiver of, or deprive that Party of the right thereafter to insist upon strict adherence to, that term or any other term of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;17. <U>Entire Agreement; Amendments</U>. This Agreement contains the entire understanding of the Parties with respect to the
subject matter hereof. This Agreement may only be amended pursuant to a written agreement executed by each Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;18.
<U>Successors and Assigns</U>. This Agreement may not be transferred or assigned by any Party without the prior written consent of the other Party. Any purported assignment without such consent is null and void. Subject to the foregoing, this
Agreement shall be binding upon, inure to the benefit of, and be enforceable by and against the permitted successors and assigns of each Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;19. <U>No Joint Liability.</U>&nbsp;Notwithstanding anything to the contrary in
this Agreement, all representations, warranties, covenants, liabilities and obligations under this Agreement are several, and not joint, except among the members of Rubric collectively as a Party to this Agreement and among the members of Velan
collectively as a Party to this Agreement, and neither Rubric nor Velan will be liable for any breach, default, liability or other obligation of such other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;20. <U>No Third-Party Beneficiaries</U>. This Agreement is solely for the benefit of the Parties and is not enforceable by any
other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;21. <U>Interpretation and Construction</U>. Each Party acknowledges that it has been represented by
independent counsel of its choice throughout all negotiations that have preceded the execution of this Agreement, and that it has executed the same with the advice of said independent counsel. Each Party and its counsel cooperated and participated
in the drafting and preparation of this Agreement and the documents referred to herein, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the Parties and may not be construed against any
Party by reason of its drafting or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any Party that drafted or prepared it is of no application and is
hereby expressly waived by each Party, and any controversy over any interpretation of this Agreement shall be decided without regards to events of drafting or preparation. The section headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this Agreement. In this Agreement, (i)&nbsp;the word &#147;including&#148; (in its various forms) means &#147;including, without limitation,&#148; (ii) the words
&#147;hereunder,&#148; &#147;hereof,&#148; &#147;hereto&#148; and words of similar import are references to this Agreement as a whole and not to any particular provision of this Agreement, and (iii)&nbsp;the word &#147;or&#148; is not exclusive.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;22. <U>Certain Defined Terms</U>. For purposes of this Agreement: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Affiliate</U>&#148; has the meaning set forth in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated by the SEC under
the Exchange Act, and shall include all persons or entities that at any time during the term of this Agreement become Affiliates of any person or entity referred to in this Agreement; <U>provided</U>, <U>however</U>, that the term
&#147;Affiliate&#148; shall not include any publicly-traded portfolio company in which any member of the Investor Group has a minority investment; <U>provided</U>, <U>further</U>, that, for purposes of this Agreement, no member of the Investor Group
shall be deemed an Affiliate of the Company and the Company shall not be deemed an Affiliate of any member of the Investor Group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
&#147;<U>Beneficial Ownership</U>&#148; has the meaning of such term under or as used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated by the SEC under the Exchange Act, except that a person shall also be deemed to have Beneficial
Ownership of all Voting Securities which such person has the right or ability to vote, cause to be voted or control or direct the voting of any Voting Securities (in each case whether directly or indirectly, including pursuant to any agreement,
arrangement or understanding, whether or not in writing); <U>provided</U>, that a person shall be deemed to have &#147;Beneficial Ownership&#148; of any Voting Securities that such person has a right, option or obligation to own, acquire or control
or direct the voting of upon conversion, exercise, expiration, settlement or similar event (&#147;<U>Exercise</U>&#148;) under or pursuant to (i)&nbsp;any Derivative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(whether such Derivative is subject to Exercise immediately or only after the passage of time or upon the satisfaction of one or more conditions) and (ii)&nbsp;any Synthetic Position that is
required or permitted to be settled, in whole or in part, in Voting Securities. A person shall be deemed to be the &#147;<U>Beneficial Owner</U>&#148; of, or to &#147;<U>beneficially own</U>,&#148; any securities that such person has Beneficial
Ownership of. For purposes of this Agreement, references to the aggregate Beneficial Ownership of the Investor Group shall be determined irrespective of whether the members thereto remain as part of a &#147;group&#148; for purposes of the Exchange
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Business Day</U>&#148; means any day that is not (i)&nbsp;a Saturday, (ii)&nbsp;a Sunday or (iii)&nbsp;other day on
which commercial banks in the State of New York are authorized or required to be closed by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<U>Change of
Control</U>&#148; means, with respect to the Company, any transaction or series of related transactions in which a person or a group becomes the Beneficial Owner of Voting Securities of the Company constituting 50% or more of the total voting power
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Common Stock</U>&#148; means the common stock, $0.01 par value per share, of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Cooperation Period</U>&#148; means the period commencing with the execution of this Agreement and ending on the Initial Trigger
Date; <U>provided</U>, <U>however</U>, that the Cooperation Period shall be extended until the Second Trigger Date if (A)&nbsp;the Company notifies the Investor Group and the Investor Group Appointees in writing at least ten (10)&nbsp;days prior to
the Initial Trigger Date that the Board irrevocably offers to nominate each of the Investor Group Appointees for election at the Company&#146;s 2024 annual meeting of stockholders (the &#147;<U>2024 Annual Meeting</U>&#148;) and (B)&nbsp;the
Investor Group and&nbsp;the Investor Group Appointees agree to such nomination within ten (10)&nbsp;days of receipt of such notice. If the Investor Group does not accept such renomination within such ten (10)&nbsp;day period, then the Cooperation
Period shall terminate as scheduled on the Initial Trigger Date and each Investor Group Appointee shall resign from the Board pursuant to the letter executed pursuant to <U>Section</U><U></U><U>&nbsp;1(a)(ii)</U> upon delivery of a notice of an
intent to nominate directors for election at the 2024 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Extraordinary Transaction</U>&#148; means any merger,
acquisition, tender or exchange offer, recapitalization, reorganization, financing, liquidation, disposition of all or substantially all of the assets of the Company, <FONT STYLE="white-space:nowrap">spin-off,</FONT>
<FONT STYLE="white-space:nowrap">split-off,</FONT> or other business combination or similar transaction involving the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
&#147;<U>Initial Trigger Date</U>&#148; means the date that is the earlier of (i)&nbsp;thirty (30) days prior to the deadline for nomination of directors and stockholder proposals pursuant to the Bylaws for the 2024 Annual Meeting and (ii)&nbsp;one
hundred and twenty (120)&nbsp;days prior to the first anniversary of the 2023 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Representatives</U>&#148;
means, as to any person, such person&#146;s and its and their respective directors, officers, employees, partners, members, managers, agents or other representatives, in each case, acting on its behalf; <U>provided</U>, <U>however</U>, that any
reference to &#147;controlled Affiliates&#146; Representatives&#148; shall not include such controlled Affiliate&#146;s employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) &#147;<U>Second Trigger Date</U>&#148; means the date that is the earlier of
(i)&nbsp;thirty (30) days prior to the deadline for director nominations and stockholder proposals pursuant to the Bylaws for the Company&#146;s 2025 annual meeting of stockholders (the &#147;<U>2025 Annual Meeting</U>&#148;) and (ii)&nbsp;one
hundred and twenty (120)&nbsp;days prior to the first anniversary of the 2024 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#147;<U>SEC</U>&#148; means the U.S.
Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) &#147;<U>Synthetic Position</U>&#148; means any option, warrant, convertible security, stock
appreciation right or other security, contract right or derivative position or similar right (including any &#147;swap&#148; transaction with respect to any security, other than a broad based market basket or index) (each of the foregoing, a
&#147;<U>Derivative</U>&#148;), whether or not presently exercisable, that has an exercise or conversion privilege or a settlement payment or mechanism at a price related to the value of Voting Securities or a value determined in whole or in part
with reference to, or derived in whole or in part from, the value of Voting Securities and that increases in value as the market price or value of Voting Securities increases or that provides an opportunity, directly or indirectly, to profit or
share in any profit derived from any increase in the value of Voting Securities, in each case regardless of whether (x)&nbsp;it conveys any voting rights in such Voting Securities to any person, (y)&nbsp;it is required to be or capable of being
settled, in whole or in part, in Voting Securities, or (z)&nbsp;any person (including the holder of such Synthetic Position) may have entered into other transactions that hedge its economic effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) &#147;<U>Voting Securities</U>&#148; means the Common Stock and any other securities of the Company entitled to vote in the election of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Pages Follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each Party has executed this Agreement or caused the same to be executed
by its duly authorized representative as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HERON THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Barry Quart</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Barry Quart, Pharm.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Chairman of the Board</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Cooperation Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each Party has executed this Agreement or caused the same to be executed
by its duly authorized representative as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RUBRIC CAPITAL MANAGEMENT LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rubric Capital Management GP LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">General
Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Rosen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Rosen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Rosen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>DAVID ROSEN</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VELAN CAPITAL MASTER FUND LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Velan Capital Holdings LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">General
Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Adam Morgan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Adam Morgan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VELAN CAPITAL HOLDINGS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Adam Morgan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Adam Morgan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VELAN CAPITAL INVESTMENT MANAGEMENT LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Velan Capital Management LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">General
Partner</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Adam Morgan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Adam Morgan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Cooperation Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>VELAN CAPITAL MANAGEMENT LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Adam Morgan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Adam Morgan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Adam Morgan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>ADAM MORGAN</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Balaji Venkataraman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><B>BALAJI VENKATARAMAN</B></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to
Cooperation Agreement] </I></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE A </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rubric Capital Management LP, a Delaware limited partnership </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">David Rosen </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE B </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Velan Capital Master Fund LP, a Cayman Islands exempted limited partnership </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Velan Capital Holdings LLC, a Delaware limited liability company </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Velan Capital Investment Management LP, a Delaware limited partnership </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Velan Capital Management LLC, a Delaware limited liability company </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Adam Morgan </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Balaji Venkataraman </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>IRREVOCABLE LETTER OF RESIGNATION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February [&#149;], 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4242 Campus Point Court, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92121
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This irrevocable resignation is
delivered pursuant to that certain Cooperation Agreement (the &#147;<U>Agreement</U>&#148;), dated as of February [&#149;], 2023, by and between Heron Therapeutics, Inc. (the &#147;<U>Company</U>&#148;) and the Investor Group (as such term is
defined therein). Capitalized terms used herein but not defined shall have the meaning set forth in the Agreement. Effective upon, and subject to, such time as [(i) Velan fails at any time after the date of the Agreement to maintain the Velan
Minimum Ownership Level or (ii)]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> the delivery of a notice of an intent to nominate directors at the 2024 Annual Meeting made by, or on behalf of, any member of the Investor Group, I hereby resign
from my position as a director of the Company and from any and all committees of the Board on which I serve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This resignation may not be withdrawn by me
at any time during which it is effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is understood and agreed that the Board has the sole and exclusive authority to determine whether or not to
accept any such resignation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Note</U></B>: Prong (i)&nbsp;will only be included in the Resignation Letter to be signed by the Velan
Principal Appointee. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT B </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FORM OF </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>REPLACEMENT DIRECTOR IRREVOCABLE LETTER OF RESIGNATION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4242 Campus Point Court, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California 92121
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This irrevocable resignation is
delivered pursuant to that certain Cooperation Agreement (the &#147;<U>Agreement</U>&#148;), dated as of February [&#149;], 2023, by and between Heron Therapeutics, Inc. (the &#147;<U>Company</U>&#148;) and the Investor Group (as such term is
defined therein). Capitalized terms used herein but not defined shall have the meaning set forth in the Agreement. Effective upon, and subject to, such time as [(i) Velan fails at any time after the date of the Agreement to maintain the Velan
Minimum Ownership Level or (ii)]<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> the delivery of a notice of an intent to nominate directors at the 2024 Annual Meeting made by, or on behalf of, any member of the Investor Group, I hereby resign
from my position as a director of the Company and from any and all committees of the Board on which I serve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This resignation may not be withdrawn by me
at any time during which it is effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is understood and agreed that the Board has the sole and exclusive authority to determine whether or not to
accept any such resignation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U></U><U></U><U></U>] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Note</U></B>: Prong (i)&nbsp;will only be included in the Resignation Letter to be signed by any
Replacement Director for the Velan Principal Appointee. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT C </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Press Release </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Appoints Three New Independent Directors </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO&#151;February 22, 2023&#151;</B>Heron Therapeutics, Inc. (NASDAQ: HRTX) (&#147;Heron&#148; or the &#147;Company&#148;), a commercial-stage
biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that it has entered into a cooperation agreement with two of its shareholders,
Rubric Capital Management LP (&#147;Rubric&#148;) and Velan Capital Investment Management LP (&#147;Velan&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the agreement, Heron has
agreed to appoint Craig Collard, former President&nbsp;&amp; Chief Executive Officer at Veloxis Pharmaceuticals, and Adam Morgan, Chief Investment Officer at Velan, to the Company&#146;s Board of Directors (the &#147;Board&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, as a result of Heron&#146;s ongoing refreshment process, the Company will appoint Kevin Kotler, Founder and Portfolio Manager of Broadfin
Capital, to the Board. Current directors Stephen Davis and Kimberly Manhard will be leaving the Board. With these changes, the Heron Board will expand to eight directors, seven of whom are independent, and all of whom will stand for election to the
Board at the upcoming 2023 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron also announced it will separate the roles of Chairman and CEO after the conclusion of its 2023 Annual
Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Heron is committed to the ongoing renewal of its Board to ensure we maintain diverse and qualified directors who are charged with
assisting to drive shareholder value,&#148; said Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron. &#147;Craig, Adam and Kevin bring valuable expertise to the Board, and we are confident that Heron shareholders will benefit
greatly from their experience across the medical technology, pharmaceuticals and healthcare industries. On behalf of the entire Board and management team, I would like to thank Stephen Davis and Kimberly Manhard for their service as directors of
Heron.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quart continued, &#147;Today, Heron has a strong portfolio of four commercialized products, and we have made important advances in both our
acute care and oncology care franchises. In 2023, we expect significant potential growth of ZYNRELEF, the launch of APONVIE in the U.S., and continued growth of our oncology care franchise. I look forward to working alongside Craig, Adam and Kevin
and my other fellow Board members, as well as the management team, to build on the momentum we have underway.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Rosen, Managing Partner of
Rubric, said, &#147;We appreciate the dialogue we have had with the Heron Board and management team and are confident that the changes announced today will help Heron focus on the goal of enhancing value for all shareholders. With a refreshed and
aligned Board, we believe that Heron is poised for continued growth and value creation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam Morgan, Chief Investment Officer of Velan, said,
&#147;Velan invested in Heron because we believe it represents an undervalued company despite its advanced science, patented technologies, and an </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
innovative approach to drug discovery and development. I look forward to working closely with my fellow directors to help enhance value for all shareholders.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the cooperation agreement, Rubric and Velan have agreed to customary standstill, voting commitments and other provisions. A copy of the
cooperation agreement will be included in a Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Craig Collard </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Collard most recently
served as the Chief Executive Officer of Veloxis Pharmaceutics A/S (now Veloxis Pharmaceuticals Inc., &#147;Veloxis&#148;) before it was acquired by Asahi Kasei Corp, a transplant focused pharmaceutical company with its principal office in Cary,
North Carolina, from 2015 to December 2021, and remains on the Veloxis board of advisors. Prior to joining Veloxis, Mr.&nbsp;Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc.,
a pharmaceutical company (&#147;Cornerstone&#148;), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. in 2014. Mr.&nbsp;Collard also served as Cornerstone&#146;s Interim Chief Financial Officer, from 2010 to 2011, and as its President,
from 2008 to 2011. Mr.&nbsp;Collard served as the Founder, President and Chief Executive Officer of Cornerstone BioPharma Inc. (formerly Cornerstone BioPharma Holdings, Ltd.), a pharmaceutical company, and as a member of its board of directors, from
2004 to 2008. Prior to that, Mr.&nbsp;Collard served as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company that he founded in 2003. From 2002 to 2003, Mr.&nbsp;Collard served as Vice President
of Sales for Verum Pharmaceuticals, Inc., a specialty pharmaceutical company. Mr.&nbsp;Collard currently serves on the board of directors of Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company in Santa Monica, California developing
therapies to treat substance use disorders and drug overdoses, since October 2018 and as Chairman, since January 2021. Mr.&nbsp;Collard has also served on the board of directors of TerrAscend Corp., a North American cannabis operator based in
Mississauga, Canada, since December 2018. Mr.&nbsp;Collard previously served as a member of the board of directors of Sierra Oncology, Inc., a San Mateo, California-based late-stage biopharmaceutical company acquired by GlaxoSmithKline plc, from May
2020 to July 2022. Mr.&nbsp;Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kevin Kotler </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Kotler has over 30 years of
experience as an investor and analyst focused on the healthcare industry. Since <FONT STYLE="white-space:nowrap">mid-2020,</FONT> Mr.&nbsp;Kotler invests through Broadfin Holdings, a family office focused on investing in public and private companies
across all sectors. From 2005 to 2020, he was the Founder and Portfolio Manager of Broadfin Capital, LLC, a healthcare focused investment fund which utilized passive and activist investment strategies in public and private medical technology,
biotechnology and pharmaceutical companies. Since <FONT STYLE="white-space:nowrap">mid-2021,</FONT> Mr.&nbsp;Kotler has been a member of New York Angels, a New York based investment group focused on early-stage companies. He also serves on the board
of Curonix a privately held company and previously served on the board of Biodelivery Sciences International and Avadel Pharmaceuticals plc. Mr.&nbsp;Kotler was previously a board member of the Memorial Sloan-Kettering Cancer Center Technology
Development Fund. He is <FONT STYLE="white-space:nowrap">co-founder</FONT> of Hamptons United, a charity started as a result of the coronavirus pandemic to help support local charities on the east end of Long Island. Kevin graduated from the Wharton
School at the University of Pennsylvania in 1993 with a Bachelor of Science degree in Economics. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Adam Morgan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Morgan currently serves as the Chief Investment Officer of Velan Capital Investment Management LP, a healthcare-dedicated investment firm based in
Alpharetta, Georgia. Mr.&nbsp;Morgan also currently serves on the board of directors of Health Outlook Corporation, a privately-held developer of predictive healthcare technology and service based in New York, New York, where he serves as a director
and chair of the company&#146;s audit committee, since January 2023. Previously, Mr.&nbsp;Morgan served as Senior Analyst at Broadfin Capital, LLC, a healthcare dedicated investment firm based in New York, New York, where he covered the Biotech and
Pharmaceutical sectors, from February 2018 to June 2020. Prior to that, Mr.&nbsp;Morgan served as Senior Analyst at Iguana Healthcare Partners LLC, a healthcare-dedicated investment firm based in New York, New York, where he covered Medical Devices
and Specialty Pharmaceuticals, from 2015 to January 2018. Mr.&nbsp;Morgan also served as Analyst at Pura Vida Investments, LLC, a healthcare-focused investment firm, where he covered global Medical Devices, from 2014 to 2015. Earlier in his career,
Mr.&nbsp;Morgan served as a Research Associate at Cowen and Company (a subsidiary of Cowen Inc.), a financial services company, on the firm&#146;s Medical Supplies and Devices team, from January 2014 to June 2014. Mr.&nbsp;Morgan received his B.S.
in Chemistry from the University of Minnesota and his MBA from the Carlson School of Management at the University of Minnesota. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ZYNRELEF for
Postoperative Pain </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic
bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and significantly increased proportion of
patients requiring no opioids&nbsp;through the first 72 hours following surgery compared to bupivacaine solution, the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> local anesthetic for
postoperative pain control. ZYNRELEF was initially approved by the FDA in&nbsp;May 2021&nbsp;for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal
herniorrhaphy and total knee arthroplasty. In December 2021, the FDA approved an expansion of ZYNRELEF&#146;s indication. ZYNRELEF is now indicated in the U.S. in adults for soft tissue or periarticular instillation to produce postsurgical analgesia
for up to 72 hours after foot and ankle, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">small-to-medium</FONT></FONT> open abdominal, and lower extremity total joint arthroplasty surgical procedures. Safety and efficacy have not
been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. In&nbsp;September 2020, the&nbsp;European Commission&nbsp;granted a marketing authorization for ZYNRELEF for the treatment
of somatic postoperative pain from small- to <FONT STYLE="white-space:nowrap">medium-sized</FONT> surgical wounds in adults.&nbsp;As of&nbsp;January 1, 2021, ZYNRELEF is approved in 31 European countries including the countries of the&nbsp;European
Union&nbsp;and European Economic Area and the&nbsp;United Kingdom. In March 2022, Health Canada issued a Notice of Compliance for ZYNRELEF for instillation into the surgical wound for postoperative analgesia after bunionectomy, open inguinal
herniorrhaphy, and total knee arthroplasty surgical procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing information, including Boxed Warning, at
<U>www.ZYNRELEF.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About APONVIE&nbsp;for Postoperative Nausea and Vomiting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">APONVIE (aprepitant) injectable emulsion is a substance NK<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB> RA, indicated for the prevention of
postoperative nausea and vomiting in adults. Delivered via a <FONT STYLE="white-space:nowrap">30-second</FONT> intravenous (IV)&nbsp;injection, APONVIE 32 mg was demonstrated to be bioequivalent to oral aprepitant 40 mg with rapid achievement of
therapeutic drug levels. APONVIE is the same formulation as Heron&#146;s approved CINVANTI. APONVIE is supplied in a single-dose vial that delivers the full 32 mg dose for PONV. APONVIE was approved by the FDA in September 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing information at <U>www.APONVIE.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CINVANTI for Chemotherapy Induced Nausea and Vomiting (CINV) Prevention </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with
initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy
(MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a <FONT STYLE="white-space:nowrap">3-day</FONT> regimen. CINVANTI is an IV formulation of aprepitant, an NK<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB> RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;capsules. Aprepitant
(including its prodrug, fosaprepitant) is the only single-agent NK<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB>&nbsp;RA to significantly reduce nausea and vomiting in both the acute phase (0&#150;24 hours after chemotherapy) and the
delayed phase (24&#150;120 hours after chemotherapy). <FONT STYLE="white-space:nowrap">The&nbsp;FDA-approved</FONT> dosing administration included in&nbsp;the U.S.&nbsp;prescribing information for CINVANTI include 100 mg or 130 mg administered as a <FONT
STYLE="white-space:nowrap">30-minute</FONT> IV infusion or a <FONT STYLE="white-space:nowrap">2-minute</FONT> IV injection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing
information at&nbsp;<U>www.CINVANTI.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About SUSTOL for CINV Prevention </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and
repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable <FONT STYLE="white-space:nowrap">5-hydroxytryptamine</FONT> type 3 RA
that utilizes Heron&#146;s Biochronomer<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;drug delivery technology to maintain therapeutic levels of granisetron for &#8805;5 days. The SUSTOL global Phase 3 development program was
comprised of two, large, guideline-based clinical studies that evaluated SUSTOL&#146;s efficacy and safety in more than 2,000 patients with cancer. SUSTOL&#146;s efficacy in preventing nausea and vomiting was evaluated in both the acute phase
(0&#150;24 hours after chemotherapy) and delayed phase (24&#150;120 hours after chemotherapy). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing information
at&nbsp;<U>www.SUSTOL.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Heron Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic
innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for acute care and oncology patients. For more information, visit <U>www.herontx.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains
&#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management&#146;s expectations and assumptions as of the date of this news
release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, uncertainties related to market conditions; the potential market opportunities for ZYNRELEF, APONVIE,
CINVANTI and SUSTOL; and other risks and uncertainties identified in the Company&#146;s filings with the&nbsp;U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no
obligation to update or revise these statements except as may be required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations and Media Contact</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Szekeres </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Operating Officer
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dszekeres@herontx.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">858-251-4447</FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d457589dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Appoints Three New Independent Directors </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO&#151;February 22, 2023&#151;</B>Heron Therapeutics, Inc. (NASDAQ: HRTX) (&#147;Heron&#148; or the &#147;Company&#148;), a commercial-stage
biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced that it has entered into a cooperation agreement with two of its shareholders,
Rubric Capital Management LP (&#147;Rubric&#148;) and Velan Capital Investment Management LP (&#147;Velan&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the agreement, Heron has
agreed to appoint Craig Collard, former President&nbsp;&amp; Chief Executive Officer at Veloxis Pharmaceuticals, and Adam Morgan, Chief Investment Officer at Velan, to the Company&#146;s Board of Directors (the &#147;Board&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, as a result of Heron&#146;s ongoing refreshment process, the Company will appoint Kevin Kotler, Founder and Portfolio Manager of Broadfin
Capital, to the Board. Current directors Stephen Davis and Kimberly Manhard will be leaving the Board. With these changes, the Heron Board will expand to eight directors, seven of whom are independent, and all of whom will stand for election to the
Board at the upcoming 2023 Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron also announced it will separate the roles of Chairman and CEO after the conclusion of its 2023 Annual
Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Heron is committed to the ongoing renewal of its Board to ensure we maintain diverse and qualified directors who are charged with
assisting to drive shareholder value,&#148; said Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron. &#147;Craig, Adam and Kevin bring valuable expertise to the Board, and we are confident that Heron shareholders will benefit
greatly from their experience across the medical technology, pharmaceuticals and healthcare industries. On behalf of the entire Board and management team, I would like to thank Stephen Davis and Kimberly Manhard for their service as directors of
Heron.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quart continued, &#147;Today, Heron has a strong portfolio of four commercialized products, and we have made important advances in both our
acute care and oncology care franchises. In 2023, we expect significant potential growth of ZYNRELEF, the launch of APONVIE in the U.S., and continued growth of our oncology care franchise. I look forward to working alongside Craig, Adam and Kevin
and my other fellow Board members, as well as the management team, to build on the momentum we have underway.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Rosen, Managing Partner of
Rubric, said, &#147;We appreciate the dialogue we have had with the Heron Board and management team and are confident that the changes announced today will help Heron focus on the goal of enhancing value for all shareholders. With a refreshed and
aligned Board, we believe that Heron is poised for continued growth and value creation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adam Morgan, Chief Investment Officer of Velan, said,
&#147;Velan invested in Heron because we believe it represents an undervalued company despite its advanced science, patented technologies, and an innovative approach to drug discovery and development. I look forward to working closely with my fellow
directors to help enhance value for all shareholders.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the cooperation agreement, Rubric and Velan have agreed to customary standstill, voting
commitments and other provisions. A copy of the cooperation agreement will be included in a Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Craig Collard </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Collard most recently
served as the Chief Executive Officer of Veloxis Pharmaceutics A/S (now Veloxis Pharmaceuticals Inc., &#147;Veloxis&#148;) before it was acquired by Asahi Kasei Corp, a transplant focused pharmaceutical company with its principal office in Cary,
North Carolina, from 2015 to December 2021, and remains on the Veloxis board of advisors. Prior to joining Veloxis, Mr.&nbsp;Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc.,
a pharmaceutical company (&#147;Cornerstone&#148;), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. in 2014. Mr.&nbsp;Collard also served as Cornerstone&#146;s Interim Chief Financial Officer, from 2010 to 2011, and as its President,
from 2008 to 2011. Mr.&nbsp;Collard served as the Founder, President and Chief Executive Officer of Cornerstone BioPharma Inc. (formerly Cornerstone BioPharma Holdings, Ltd.), a pharmaceutical company, and as a member of its board of directors, from
2004 to 2008. Prior to that, Mr.&nbsp;Collard served as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company that he founded in 2003. From 2002 to 2003, Mr.&nbsp;Collard served as Vice President
of Sales for Verum Pharmaceuticals, Inc., a specialty pharmaceutical company. Mr.&nbsp;Collard currently serves on the board of directors of Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company in Santa Monica, California developing
therapies to treat substance use disorders and drug overdoses, since October 2018 and as Chairman, since January 2021. Mr.&nbsp;Collard has also served on the board of directors of TerrAscend Corp., a North American cannabis operator based in
Mississauga, Canada, since December 2018. Mr.&nbsp;Collard previously served as a member of the board of directors of Sierra Oncology, Inc., a San Mateo, California-based late-stage biopharmaceutical company acquired by GlaxoSmithKline plc, from May
2020 to July 2022. Mr.&nbsp;Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kevin Kotler </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Kotler has over 30 years of
experience as an investor and analyst focused on the healthcare industry. Since <FONT STYLE="white-space:nowrap">mid-2020,</FONT> Mr.&nbsp;Kotler invests through Broadfin Holdings, a family office focused on investing in public and private companies
across all sectors. From 2005 to 2020, he was the Founder and Portfolio Manager of Broadfin Capital, LLC, a healthcare focused investment fund which utilized passive and activist investment strategies in public and private medical technology,
biotechnology and pharmaceutical companies. Since <FONT STYLE="white-space:nowrap">mid-2021,</FONT> Mr.&nbsp;Kotler has been a member of New York Angels, a New York based investment group focused on early-stage companies. He also serves on the board
of Curonix a privately held company and previously served on the board of Biodelivery Sciences International and Avadel Pharmaceuticals plc. Mr.&nbsp;Kotler was previously a board member of the Memorial Sloan-Kettering Cancer Center Technology
Development Fund. He is <FONT STYLE="white-space:nowrap">co-founder</FONT> of Hamptons United, a charity started as a result of the coronavirus pandemic to help support local charities on the east end of Long Island. Kevin graduated from the Wharton
School at the University of Pennsylvania in 1993 with a Bachelor of Science degree in Economics. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Adam Morgan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Morgan currently serves as the Chief Investment Officer of Velan Capital Investment Management LP, a healthcare-dedicated investment firm based in
Alpharetta, Georgia. Mr.&nbsp;Morgan also currently serves on the board of directors of Health Outlook Corporation, a privately-held developer of predictive healthcare technology and service based in New York, New York, where he serves as a director
and chair of the company&#146;s audit committee, since January 2023. Previously, Mr.&nbsp;Morgan served as Senior Analyst at Broadfin Capital, LLC, a healthcare dedicated investment firm based in New York, New York, where he covered the Biotech and
Pharmaceutical sectors, from February 2018 to June 2020. Prior to that, Mr.&nbsp;Morgan served as Senior Analyst at Iguana Healthcare Partners LLC, a healthcare-dedicated investment firm based in New York, New York, where he covered Medical Devices
and Specialty Pharmaceuticals, from 2015 to January 2018. Mr.&nbsp;Morgan also served as Analyst at Pura Vida Investments, LLC, a healthcare-focused investment firm, where he covered global Medical Devices, from 2014 to 2015. Earlier in his career,
Mr.&nbsp;Morgan served as a Research Associate at Cowen and Company (a subsidiary of Cowen Inc.), a financial services company, on the firm&#146;s Medical Supplies and Devices team, from January 2014 to June 2014. Mr.&nbsp;Morgan received his B.S.
in Chemistry from the University of Minnesota and his MBA from the Carlson School of Management at the University of Minnesota. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ZYNRELEF for
Postoperative Pain </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZYNRELEF is the first and only dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic
bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and significantly increased proportion of
patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution, the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> local anesthetic for
postoperative pain control. ZYNRELEF was initially approved by the FDA in May 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy
and total knee arthroplasty. In December 2021, the FDA approved an expansion of ZYNRELEF&#146;s indication. ZYNRELEF is now indicated in the U.S. in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72
hours after foot and ankle, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">small-to-medium</FONT></FONT> open abdominal, and lower extremity total joint arthroplasty surgical procedures. Safety and efficacy have not been
established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures. In September 2020, the European Commission granted a marketing authorization for ZYNRELEF for the treatment of somatic
postoperative pain from small- to <FONT STYLE="white-space:nowrap">medium-sized</FONT> surgical wounds in adults. As of January 1, 2021, ZYNRELEF is approved in 31 European countries including the countries of the European Union and European
Economic Area and the United Kingdom. In March 2022, Health Canada issued a Notice of Compliance for ZYNRELEF for instillation into the surgical wound for postoperative analgesia after bunionectomy, open inguinal herniorrhaphy, and total knee
arthroplasty surgical procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing information, including Boxed Warning, at <U>www.ZYNRELEF.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About APONVIE&nbsp;for Postoperative Nausea and Vomiting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">APONVIE (aprepitant) injectable emulsion is a substance NK<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB> RA, indicated for the prevention of
postoperative nausea and vomiting in adults. Delivered via a <FONT STYLE="white-space:nowrap">30-second</FONT> intravenous (IV)&nbsp;injection, APONVIE 32 mg was demonstrated to be bioequivalent to oral aprepitant 40 mg with rapid achievement of
therapeutic drug levels. APONVIE is the same formulation as Heron&#146;s approved CINVANTI. APONVIE is supplied in a single-dose vial that delivers the full 32 mg dose for PONV. APONVIE was approved by the FDA in September 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing information at <U>www.APONVIE.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CINVANTI for Chemotherapy Induced Nausea and Vomiting (CINV) Prevention </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with
initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy
(MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a <FONT STYLE="white-space:nowrap">3-day</FONT> regimen. CINVANTI is an IV formulation of aprepitant, an NK<SUB
STYLE="font-size:75%; vertical-align:bottom">1</SUB> RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;capsules. Aprepitant
(including its prodrug, fosaprepitant) is the only single-agent NK<SUB STYLE="font-size:75%; vertical-align:bottom">1</SUB>&nbsp;RA to significantly reduce nausea and vomiting in both the acute phase (0&#150;24 hours after chemotherapy) and the
delayed phase (24&#150;120 hours after chemotherapy). <FONT STYLE="white-space:nowrap">The&nbsp;FDA-approved</FONT> dosing administration included in&nbsp;the U.S.&nbsp;prescribing information for CINVANTI include 100 mg or 130 mg administered as a <FONT
STYLE="white-space:nowrap">30-minute</FONT> IV infusion or a <FONT STYLE="white-space:nowrap">2-minute</FONT> IV injection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing
information at&nbsp;<U>www.CINVANTI.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About SUSTOL for CINV Prevention </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and
repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable <FONT STYLE="white-space:nowrap">5-hydroxytryptamine</FONT> type 3 RA
that utilizes Heron&#146;s Biochronomer<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&nbsp;drug delivery technology to maintain therapeutic levels of granisetron for &#8805;5 days. The SUSTOL global Phase 3 development program was
comprised of two, large, guideline-based clinical studies that evaluated SUSTOL&#146;s efficacy and safety in more than 2,000 patients with cancer. SUSTOL&#146;s efficacy in preventing nausea and vomiting was evaluated in both the acute phase
(0&#150;24 hours after chemotherapy) and delayed phase (24&#150;120 hours after chemotherapy). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please see full prescribing information
at&nbsp;<U>www.SUSTOL.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Heron Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic
innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for acute care and oncology patients. For more information, visit <U>www.herontx.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release contains
&#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management&#146;s expectations and assumptions as of the date of this news
release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, uncertainties related to market conditions; the potential market opportunities for ZYNRELEF, APONVIE,
CINVANTI and SUSTOL; and other risks and uncertainties identified in the Company&#146;s filings with the&nbsp;U.S. Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no
obligation to update or revise these statements except as may be required by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations and Media Contact</B>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Szekeres </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Operating Officer
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dszekeres@herontx.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">858-251-4447</FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>hrtx-20230221.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/22/2023 4:11:00 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:hrtx="http://www.herontx.com/20230221"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.herontx.com/20230221"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20230221_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20230221_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>hrtx-20230221_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/22/2023 4:11:00 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>hrtx-20230221_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 2/22/2023 4:11:00 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="hrtx-20230221.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140197220197296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HERON THERAPEUTICS, INC. /DE/<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 21,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-2875566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4242 Campus Point Court<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-4400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HRTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d457589d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hrtx-20230221.xsd" xlink:type="simple"/>
    <context id="duration_2023-02-21_to_2023-02-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818033</identifier>
        </entity>
        <period>
            <startDate>2023-02-21</startDate>
            <endDate>2023-02-21</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2023-02-21_to_2023-02-21"
      id="Hidden_dei_EntityRegistrantName">HERON THERAPEUTICS, INC. /DE/</dei:EntityRegistrantName>
    <dei:SecurityExchangeName
      contextRef="duration_2023-02-21_to_2023-02-21"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2023-02-21_to_2023-02-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-02-21_to_2023-02-21"
      id="Hidden_dei_EntityCentralIndexKey">0000818033</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-02-21_to_2023-02-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-02-21_to_2023-02-21">2023-02-21</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-02-21_to_2023-02-21">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-02-21_to_2023-02-21">001-33221</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-02-21_to_2023-02-21">94-2875566</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-02-21_to_2023-02-21">4242 Campus Point Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-02-21_to_2023-02-21">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-02-21_to_2023-02-21">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-02-21_to_2023-02-21">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-02-21_to_2023-02-21">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-02-21_to_2023-02-21">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-02-21_to_2023-02-21">251-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-02-21_to_2023-02-21">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-02-21_to_2023-02-21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-02-21_to_2023-02-21">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-02-21_to_2023-02-21">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-02-21_to_2023-02-21">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-02-21_to_2023-02-21">HRTX</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-02-21_to_2023-02-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ KTA65I>*NQS     $P(   L
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( *](5E:_"/I,:@0  #T1   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " "O2%96GZ ;\+$"  #B#   #0              @ &M#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( *](5E:7BKL<P    !,"   +
M  "  8D/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *](5E8<.&7J/P$  #P"
M   /              "  7(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "O2%96)!Z;HJT   #X 0  &@              @ '>$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "O2%9699!YDAD!  #/ P
M$P              @ '#$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"   -%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d457589d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, dei:SecurityExchangeName -  d457589d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d457589d8k.htm">d457589d8k.htm</File>
    <File>d457589dex101.htm</File>
    <File>d457589dex991.htm</File>
    <File>hrtx-20230221.xsd</File>
    <File>hrtx-20230221_lab.xml</File>
    <File>hrtx-20230221_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d457589d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d457589d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hrtx-20230221_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hrtx-20230221_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hrtx-20230221.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 4
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "hrtx",
   "nsuri": "http://www.herontx.com/20230221",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d457589d8k.htm",
      "contextRef": "duration_2023-02-21_to_2023-02-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d457589d8k.htm",
      "contextRef": "duration_2023-02-21_to_2023-02-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.herontx.com//20230221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-23-044236-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-044236-xbrl.zip
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MMP6ZH]>8VKSXD=OXQ8@S210(+%-2=B\_IC=L^66$.G-\#W94V/$C"$D9G-.
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M7)4;=<:2J9A7A>P22'J;(Z$5 "!:84",8.XFL:_=Y7.BYE1FB?R&%TP1L*%
M'[,0D.R7R*5K54@1!1^6P#1J)]U(_<%3_>2 *"Y15HE:?E<($,XZ#QHO>VF
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M,-+"#5!%. <')Z38., *'55WW;'IE'P6>%Q$;4M74CZ&D1P'9RKF$@_6BN$
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MOED39S-IHRVL<<5\;_/'R+;H,V9^4K-\RSU8L<+YB,0VE)(=XMX%J3'A'G%
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MA+;;\H#<.] JO"$I)Y5J*OBGO!R7RXN:;_ FK1(5)^,TQQ_HZX0V,TET#@"
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MI Z;U;>'\QA_L#%_6ZWM]52/:";PPFED]UL(\FA;NN;:N@A3+/8[#\H1)_X
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M]<%=NQMZ$T4V-30GC=9/FM/>W"$,X%(J7QT@JQOGTX60'?AT#VS_TF./AY]
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M;H7+!E _6U]#IQ((U?)*3Z]8"ZH+U 8_Y@FF:.$M3S.P6F:48M,*TI@C6S
MLZ1<1Y.G9\!FF'.:DPBF^)]/#.CBDN]<8<EOXC3[-O!:7^L%V+@H:O$7?<Q
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MC_&OLJ.%K=V_X7OC2D#^-T]N??.>L5^>WO#TR=.MO2>[6X\?/_ZY)<G[HPV
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M4 :800* )O@! )0Z*+ G+1L=^7;+M=\IYY&:"2$+6PPI?T,Z!#1#BE;<<V"
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MJ5[]F'!W3^?S1SKRWQ=4-5OGSXJI_))DY>0]8F=3S)7T?:QFK\Z*JNPSF2_
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MN1;CKX9#58:^!H#A*4BV)!Q6C*7]#<'L*5ZYO6H&C]?^HW4)Q>TFQO!O0W!
MHX)C"TCC6;K-@X^#VZOS2JO/G6?]\LMY\]&,:W],=FUFAW;KR?EJ(;5RGN+C
M3RB393 /HK*337^;=&(LG#^F>V(O^AC:Y'5A)I]4J-=428F[?XL]ZTZS-'O4
M07:[DWF8F;MYGLW3'&0DE:_D\Y3ZVC=]JCC MS])M%1#'&D3H/Q/3*RR;TT,
M[A).>1*FL3>,N%Q=I6U6/Z[P(4U0XTI;E6<^)/WTE[V]S=W]78&L#(G=TBD_
M)S6_Z5:V[1NW?"CG8)Z8RA2^XI%F?!6+&C\SX]MO'3$N--&8*'^LD13J-ES]
M#@!+2_$=63(DMVXIKZHYR)L!KFD(KF*Z$T#W2<5V9Q/1L^K_LQDZ!-1;-Q6=
MU_+&3OL$*^R:"J^:HC6I"SGXJ;GK*]/6?T<?J-U:BK=.K/^!:+OB533/$677
MOG6%&SC+;TX1S_OB%,J,3WAS2D]<%=F?N_WW55?__+TPVE3#I 4?+>?+E^H>
M(XJ.P#0O2I>7HAT74L?\/A)',HOJ"2#H6[?;^)KAFAO6I8)Z=.?,A:"%=BE=
M9JNZ'Q,RFOSN>?NB[]Q]R^ZY,7S9D@]<NVMWS[#M?4M'!A(UHUU8%UIH3Y)N
M1)4W6_U]T&[DZ;,5??XF)_< 1SJI^UW7_CAMXX;>.?YO[#+^#75_8M$/>"ME
MZ\V;W9Z/$H$LG$O ^$+7<I.Y6$\ 7X!V&0I/US>DJ^S!-^B]F[E[#K:(4_^Y
MVNX(B5;^V\N"<) 31GG+VA9# ASL&4CSE*21.+^X6>F.-7^75ZDQX)<HN*N_
MJ#+IC27N@*=UA>EHA-0!&Z2M1G[M3%49=L0049-VU"(=:]=3[2PM >K*;JO;
MPR*EN9?8V'T'#*L7!?@!AH^,%HG31G.+I>KI=MJMJLKATT:<,O8;ES_7L<PW
M<MS[/OPNZ]+[?D: 5<G85A<X76IZ\BW.=^LM(%,C>GD,O\# G;RG.R14.;MC
M._0^BIR%15IV0=(96RZ_*-HC;K?,,"IM$Q(M4F</8%=-^;4?_&J<QIKJ+E!I
M3@84RSGUN]T!!F?_D9P]2W8]*^\<W*BH8>%T,DE">/#A(*?X\?:A(/9=0HA[
M'\+@#_4%I:]]@/?OTENM;ZDM7@@KK^Q?N<T26(D_A$K=ZQ]*T5JH\8/7#:T7
M^?\U\M9#VOX^O>UO/K:PM[O7W=[=ZKY^_?KGI4R^?K<!IGQU\AN^Y%=1_C]0
M2P,$%     @ KTA65@S=94@] P  20L  !$   !H<G1X+3(P,C,P,C(Q+GAS
M9+U6;6_;-A#^7J#_X:I/&S")DM(6BY"DZ)8&")!FA9L.^U;0TMDF1I$:227V
MO]^1DAS9B5TG&188",V[Y^ZY5_KDP[*6<(O&"JU.HRQ)(T!5ZDJH^6G4VIC;
M4HCHP]GK5R=OXAC.+RZO(8:%<XTM&+N[NTNJF5!6R]:1!9N4NF80QX/^[S??
MX,_.>@$3E,@M0LVM0P._M4)619[F>9:EOR;OQS"#W-N#BCLL(&<Y?=+\"-X6
M65:D*7SY#)^"%04WHL8Q5#<K(^8+!S^5/T, G6NE4$I<P8507)6"2_@Z,/X%
M+E69P$<I8>)AEFA:-+=8);W5I:T*6RZPYJ]? 5"^E"T4F6SKT\@GHL_#<FID
MHLV<5<XPMVJ0D5),6FA$&8V@/\8]P% AO,2N@3-NIP$T2'QZ\A%B8=QRP\T"
MC59N&0KDL^+3/M*O4*S5 R.+93+7MXP$V[:]7#P>0YZF1XSZP5&:<0210OV]
M!^'%4VJ-L9,'D+NC ,B.CX]9D&Y1JMQF!+WU=ZP3!FWNG!'3UN&%-O4YSG@K
M"=6J?UHNQ4Q@%;2H3VM4;D-G4\-Q,T=WS6NT#2_Q*9FF=GHL+&*:L;\^7WT-
MG1:=>0! :#Y1-]HXZ'KP2I=A-/9DTW^+AR+$_BK.\O@H2\A8!.I1TCLJ".S%
M1(;:/HO(NC$.)F)W-; _Q/ZPR_OC;?_L#&R/LX__V,>?O3\H_@?KX#]@HM7U
M2\F,=MKS:Z*X*+N5U1T/K\L]\D6].2P%GX=W>QUO;Y'>:_#)E=(N.!HSX4TC
MU$SW5W3IF[@8.GF",PC;J^"F-%KB_AW'&J,;-$[0BK\?AL[ PN",T+3IXV'/
M?)=\FM">&50>.-@<+R]F!$%Y=4]OP#KA//C*B\'+Z:WD<FW:M\-I9"GO<C2>
M_W.XC<&GADL02\L]E&UWU%]&6D\.WONY(0WPAV^3RYW/P_I]8(XOM=+UJN-X
MKLO6OT##_X^J^J2(V>J2&LO4@54$@AZ2":E_/TA]S7%@62']<A.A>[/4_]$/
MN\'"^,A5!9TY&-D[8=M&MNVW%JL_U%DXEUR6K5SGO ?W&ON V]4Z''G/;#>N
MOQWJ-4PQVQ[C_F8\[MU5MV[HZ[]02P,$%     @ KTA65E_F@+%_!@  N48
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M0B2Y;-JO'9)G+*;Q]H[,J2[$XFLO(G7)-.=V!&BE$5X>8X-KN1X2M6D!>*H
MNH0UN^WU742X:?-V(-\3?R54O;.-OU#F21.0S;D=@5QIA)?'V(!<KH<$<EX
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M:,-P;Z2NE^*.2[6E?^5*MHNFOWA$[?D?4$L#!!0    ( *](5E;T\Z\]R 0
M #TL   5    :')T>"TR,#(S,#(R,5]P<F4N>&ULU9IA;^(V&,??GW3?P<O>
M;-*%D-"[75'IB='VA$9;!-PV[<W)) ]@S;$CVQ3X]F<'O",0.M*[37%5D>#X
M__COYY<XL<G5AW5*T1,(23CK>&&CZ2%@,4\(FW>\I?2QC GQD%28)9AR!AUO
M ]+[</WZU=4/OH]N[OH/R$<+I3+9#H+5:M5(9H1)3I=*AY2-F*<!\GU;OS?Y
MA'[?-M=&(Z" ): 42P4"_;HD-&E'S2@*P^;[QKM]F0!LXJ$$*VBC*(CT?S-J
MH8MV&+:;332\1[=Y%(8F)(5]*<\V@LP7"OT4_XQRT0UG#"B%#;HC#+.88(K&
MUO$;U&=Q W4I12,CD]JF!/$$26,7E1+V=]M\3(UY]/H5TG\ZCTSFI1W/9&.7
MC/54T 87<^VVV0JLR-O7K(]$JU8N"2\O+X/\:+&^)&6U=0-A\.?]8!PO(,6^
M9J"9Q0=-:3>)^D>];^YML#UHZTO2EGFD 8_SU)_1+72RAOGFVVJ^*?+#R&^%
MC;5,O&O3Y#:K@E,8P0R9[:=1O]#F @1G:IV?43E\<Z($"J\YX^DF,)+@AL?+
M%)BRVRY+;IDB:M-G,R[2O",>RG/:7@B8Z0:$6OLVFK'SXT@'^EPED-ID^K*0
M),TH>"C8ZTXF]*G#5%Y[H L* E@K8 DD-HSIP'_3X>LMT]V)R^-B G:7;@Y,
M0MR8\Z<@ 6):C,R.R4Z49T9_^=SC>K3H3J42.%;%#%!SIG!A"RF> NUX):+@
M>QK:=G<$<V+",_6 4SC75[FV:&^?85?$A<A8Q#:JWCT"6+P&=C6"# L=SX\7
M>K2SZIG@:6FJ=JWQY_QRD8#H>#HG>@CP4"8(%[J:+O'04FI+/#/F,37'8 9"
M0#+8)N&DV=RI'DXEY#6_,[,QQ$MC\78=+S";0Q5FY=KZ,BOW:YFUG&'6U<-+
M8H:8.XKGY\(Z$-67TH%1B^?"&3S;H:&G>R P[>O[ROHWV%0;!X_$]<5UPK#%
M]M89;/:^/=%I/)=645-?2$6?ELTOSK$9@O:J'ZN2&SWYJ KI0%Q_6@>&+;;W
MSF"SS[\Q%QD7>6['.L70XTL]7&QZ/*GX?/@OH>J+]"S[%O"E8X#O"(6'93H%
M48WFOJ[NZ/:][CBUFHYQFN!U/]%I(#.R74AX";230>I.\*1QBS-T#&<W2722
MY6XS( S":BA+ ]0=8ZEIB]"=>?>ISD3?BC!R$6'T%:$[T_!"9WIZ]U%,^(J]
M"."^W!%\^Y8M/-<FZ;NNY(]BCV(H^!,Q"_4O(7@4PQ&,1[XM2W=F[H7^#+E4
MF/Y%LNJSB_((CG \<&TIOG.&HAE/N@)P%6Y%37U)%7U:-NZLOYA?'NEPP5G%
M>=ZQKKZ,CKU:3NXLN/RA_2E@/9ZF2[:;YLAS89T0UY?8"<,6FSO+*&-.24P4
M8?-[?3,6Q%@[\R>X$F5]@96YW=&Z<&<Q92C G'*@GY;R-77SZH!XG,W.'Q:?
MBU!?>L^YMA3=64,YZ$U?RB6(;V=9$L<9HB7>+5=W%E;LC_QA-)T012N_S/!5
M5U]NQUXM)W=63R8"FU<;QYMTRL^^W1V(ZDOHP*C%X]KZR&T*8J[[\5'PE5KH
ML2+#K.*K#"="U!?=L[8MR/]A<>0J.$K-0!>8UUZW1\R'>8E3EWP!4$L! A0#
M%     @ KTA65CM /_I0%P  +8X   X              ( !     &0T-3<U
M.#ED.&LN:'1M4$L! A0#%     @ KTA65F!N\,Z17P  N>(! !$
M     ( !?!<  &0T-3<U.#ED97@Q,#$N:'1M4$L! A0#%     @ KTA65@G)
MH1:+&   D5(  !$              ( !/'<  &0T-3<U.#ED97@Y.3$N:'1M
M4$L! A0#%     @ KTA65@S=94@] P  20L  !$              ( !]H\
M &AR='@M,C R,S R,C$N>'-D4$L! A0#%     @ KTA65E_F@+%_!@  N48
M !4              ( !8I,  &AR='@M,C R,S R,C%?;&%B+GAM;%!+ 0(4
M Q0    ( *](5E;T\Z\]R 0  #TL   5              "  12:  !H<G1X
G+3(P,C,P,C(Q7W!R92YX;6Q02P4&      8 !@!_ 0  #Y\

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
